June 29th 2023
Pegozafermin was associated with improvements in fibrosis and could contribute to a resolution of NASH, according to the results of the phase 2b ENLIVEN trial.
June 23rd 2023
Patients with anti-HDV antibodies had a significantly higher prevalence of liver cirrhosis, significantly lower prothrombin time, and a higher prevalence of HIV co-infection compared to patients who demonstrated serum anti-HDV antibody negatively.
The June 22, 2023 PDUFA date for obeticholic acid 25 mg oral tablets for the treatment of precirrhotic liver fibrosis appears to be in jeopardy after a May 23, 2023 meeting of the FDA's Gastrointestinal Drugs Advisory Committee.
Despite stable rates of heavy alcohol use, deaths from alcohol-associated liver damage have risen in the US. A new study suggests an increase in the damaging effects of alcohol use in people with metabolic syndrome could be driving this apparent increase.
The investigators also found impaired biosynthesis of short-chain fatty acids in the coprofiltrate after analyzing the intestinal microbiome of patients with NAFLD who had SARS-CoV-2, manifested by an increase in the median acetic and propionic acids, as well as a decrease in the median butyric acid.
Counties with high liver transplantation registration rates and high liver-related mortality rates had comparable data on social vulnerability index, while travel distance was relatively shorter.